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INTRODUCTION 
Depression is a chronic debilitating disease. It’s a major psychotic illness 
characterised by intense despair, sadness, loss of concentration, mental slowing, 
pessimistic worry and lack of pleasure. It is associated with physical symptoms 
like insomnia or hypersomnia, altered eating pattern with anorexia, weight loss  
and over eating.1 As in Shakessphere’s  words “Hell is empty and all the devils 
are here” it affects the quality of life in every aspect – personally, socially, 
financially. It affects not only the patient’s life, but also the care taker’s life. 
It prevails in the world since time immemorial. First recorded history is 
about Saul, an Israeli king. In the Book of Samuel, written three thousand years 
ago, it was said  that  he was  influenced by an  “evil spirit” that makes him “ 
hopeless, incapacitated, guilt-ridden” leading  to his suicide.2  Then in Greek  
period  Hippocrates described it as  melancholia: melas - black and  kohle - bile    
based on the  Greek ideology of  body fluid dependent pathology. 
According to World Health Organisation (WHO) over 4.4 % of global 
population suffer from depression.3 it is distributed over all age groups. The 
burden is fifty percent more in females and it will be the second important cause 
of global disease burden by the year 2020. The worst part is the relevance of the 
data may be tip of the ice berg. 
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Depression is an age old disease. Although the ideology behind the disease 
evolved with the ages, it’s still incomplete. The treatment of depression also 
progressed with time. In the initial period it was grim as the patients were treated 
in asylum. In current scenario with better comprehension of the pathogenesis 
there are various modalities of treatment available for the disease. The treatment 
modalities are pharmacological and non-pharmacological. Pharmacological 
intervention is the effective mode of treatment which can be supplemented by 
non-pharmacological interventions like cognitive behaviour therapy (CBT), 
computerized physical activity programme and guided self help. As the most 
accepted aetiology of major clinical depression is imbalance in amine 
neurotransmission, significant part of pharmacotherapy is based on drugs which 
ensure the balance in the neurotransmission of the central nervous system. So 
these antidepressants act by increasing the amines serotonin and noradrenalin at 
the neuronal synapse. The first generation antidepressants are Tricyclic 
Antidepressants (TCA) and Monoamine Oxidase Inhibitors (MAOIs). These 
drugs are not commonly preferred as they are associated with serious adverse 
reactions. The second generation drugs like Selective Serotonin Reuptake 
Inhibitors (SSRIs) and Serotonin Nor adrenaline  Reuptake Inhibitors (SNRIs) 
are the commonly preferred ones, as they are more selective, and their safety 
margin is definitely a notch higher than the first generation drugs 4. 
Though the SSRIs & SNRIs are the commonly prescribed drugs and of 
proven efficacy among the available drugs, there are trials in recent time that 
questions their clinical effectiveness. Another major problem with these drugs is 
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lack of patient compliance.  It is very low; almost fifty percent of the patients 
don’t adhere to therapy5.  It could be due to social stigma and also due to factors 
like cost, fear of discontinuation, drug dependence, lack of motivation and follow 
up. As the etiopathogenesis of major depressive illness is still evolving, there are 
many mysteries yet to be revealed. Any new drug which offers effectiveness is 
not only making itself an option for treatment but also unfold some of those 
mysteries. It provides new targets that also help us to understand the pathogenesis 
further. 
On the other hand due to multifactorial reasons, hyperlipidemia and 
associated co-morbid conditions like cardiovascular disease, stroke, peripheral 
vascular disease, metabolic syndromes etc. are on the rise. Incidence of 
depression is found to be more associated with chronic medical conditions like 
coronary heart syndrome, stroke and arthritis. To prevent and to treat all such 
conditions, widely prescribed drug is statin. Statins have number of pleiotropic 
effects which may be of great value in these conditions. 
Literature review on the role of statins on depression has two different 
views. One view is that the use of statins in coronary and other disorders are 
associated with some cognitive dysfunction like irritability, memory loss. This is 
based on the speculation that decreased cholesterol synthesis by statins interfere 
with receptor production. Thereby it decreases the amine mediated action in 
brain6 but meta-analysis proved otherwise. Other view is statins in animal 
experiments are found to potentiate the antidepressant effect of fluoxetine. 
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In pharmacological history we have several examples of drug discovered 
for one purpose, during the course of time found to be a drug for treating another 
disease. The amine theory of depression by itself was derived accidentally when 
iproniazid used as anti tubercular agent was found to elevate patient’s mood7. 
Statins are well known for their pleiotropic effects like improved endothelial 
function, neovascularisation of ischemic tissue, increasing progenitor cells, 
reduction of inflammation etc8., which gives it an  inherent ability to extend its 
usage. These effects whether they are due to cholesterol lowering effect or due to 
some other effects are unknown. 
As both the pathogenesis of depression and the role of statins on 
depression have divergent views till date, it provides lot of space for 
experimentation. 
In this study the antidepressant effect of various statins were evaluated on 
animal model using male albino mice by tail suspension method. 
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AIM 
 
To evaluate the antidepressant effect of various statins in Swiss male 
albino mice by tail suspension method. 
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REVIEW OF LITERATURE 
“Raze out the written troubles of the brain 
And with some sweet oblivious antidote 
Cleanse the stuffed bosom of that perilous stuff 
Which weighs upon the heart?” 
-Shakespeare, Macbeth 
 
As Shakespeare has said if such an antidote is present it would be easy to 
treat depression. But a sweet antidote is still on the search. Depression is a major 
mood disorder (MMD). Mood disorder includes a wide spectrum of illness, based 
on which side the mood swings. Manic and unipolar depressive illnesses are 
poles apart in the spectrum. Bipolar disorder is one in which the patient 
experience either elation or depression at various times. If the shift between up 
and down is fast, it is rapid cycling. Lower degree of mania is hypomania. 
Depression is a common at the same time serious psychiatric illness; it 
produces profound physical and social dysfunction and also incapacitates the 
patient functionally. It is a disease associated with enormous health problems. 
Depression is a well established risk factor for medical conditions like coronary 
artery disease, stroke and cancer9. The financial ramifications of the disease are 
tremendous. Adding burden to the bundle is the social stigma attached to it. The 
disease is often misdiagnosed and undertreated. The continuum of the disease can 
range from nonpathological grief to major depressive disorder. So it has to be 
evaluated and treated effectively. 
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Epidemiology 
Depression is one of major cause of morbidity and mortality. Worldwide 
over 350 million humans of all age group are sickened by depression. It forms a 
major component in the global load of diseases. In a survey done in 17 countries, 
it was detected that 1 in 20 people suffered a depressive episode within the 
previous year10. The depressive disorder peaks at second to fourth decade of a 
patient’s life.  So it reduces the functioning capacity of people grossly and makes 
it a leading cause of disability adjusted life year (DALY) next to cardiovascular 
disease. Taking the current trend of disease into consideration it will clearly 
overcome cardiovascular illness to top the chart. It is more common in women. 
 
FIG1: Prevalence of depression 
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Post Partum Depression (PPD) is a risk factor and has a substantial 
influence on the   poor growth of the child. The incidence of PPD in our country 
is around 15-20%.11. In Indian studies, prevalence of depression is found to be 8 
to 10 per thousand population and the prevalence rates are high in the urban 
sector. It is on the rise among teenagers. 
There is a correlation that the offspring is at the risk for depression when 
the parents suffer from it. The risk of depression is 2.7 fold when one parent is 
suffering from depression and 3 times more if both of them are suffering. 
Suicidal ideation is high in depressed population. 75% of the suicides are due to 
depression and substance abuse12. Suicidal incidence is more in male sex, singles, 
and patient with prominent symptom of hopelessness. 
Etiology of depression 
Depressive disorder etiology is very complex and it is difficult to totally 
explain it by a single social, biological or developmental factor. Several factors 
interact together to end up or augment the depressive disorder. Altered 
monoamine neurotransmission is the well proved basic pathology. 
Theories of Depression 
 Biological theories 
o Monoamine hypothesis 
o Neuroendocrine hypothesis 
o Neurotrophic hypothesis 
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 Psychosocial theories 
o Cognitive behavior theory 
o Psychodynamic theory of depression 
Biological Theories 
The monoamine hypothesis describes that depression is due to the 
functional shortfall of the monoamines 5-hydroxytryptamine (5-HT) and Nor 
adrenaline (NA) at certain region of the brain13.  While mania is due to functional 
surplus. 
 
Fig 2:  Monoamine transmission 
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The idea was accidentally discovered when the clinical effect produced by 
different drugs which alters the monoamine transmission in the brain improve or 
deteriorate the symptoms of depression. Apart from 5HT and NA, monoamines 
like dopamine and glutamate are also involved with depression. 
This theory is strengthened by the following facts 
 Pharmacological manipulation of monoamine transmission is the most 
successful therapeutic model 
 Tricyclic antidepressants and monoamine oxidase inhibitors aid 
monoamine transmission. 
 Drugs like reserpine cause depression. 
 Serotonic activity is low in CSF of the depressed patients. 
 Lack of tryptophan, a precursor of serotonin nullifies the therapeutic 
effect of fluoxetine an antidepressant drug. 
 Anhedonia –a prime feature of depression is due to lack of dopamine 
neurotransmitter14. 
 Parkinson a disorder of dopaminergic pathway is frequently associated 
with depression. 
The drawback of this theory is studies about monoamine metabolism in 
depressed community and studies about monoamine receptors in the postmortem 
brain cells of depressed cohorts gave equivocal result. Another problem is, the 
changes in neurotransmission that happens with depression are reverted back 
11 
 
within minutes to hours by antidepressants, but the therapeutic effectiveness 
takes longer duration of three to four weeks time. 
Neuroendocrine Hypothesis 15 
 
Fig 3: Endocrine abnormalities in depression 
Noradrenergic and 5-HT neurotransmitters provide input to the 
hypothalamus. Abnormalities in these signals deregulate the release of 
corticotrophin-releasing hormone (CRH) and TSH releasing hormone (TRH). 
CRH level is increased in depressed population. CRH act on the pituitary and 
increase the secretion of adrenocorticotrophic hormone (ACTH). This in turn 
increases the cortisol level. CRH also has behavioural effects which are different 
from its endocrine functions. When CRH is injected in to animal their behaviour 
become depressed. 
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Neurotrophic Hypothesis16 
Brain-Derived Neurotrophic Factor (BDNF) is essential for the 
development of neural plasticity and neurogenesis.  BDNF is decreased in 
depression. 
o Antidepressants increase the level of BDNF 
o BDNF increase the neurogenesis in cortical region like 
hippocampus. 
o Animal models exposed to chronic stress exhibit a drop in BDNF 
level 
o Changes in the cortical region that happens during chronic stress is 
similar to BDNF deficiency 
o Electro convulsive therapy increases the BDNF level. 
 
Fig 4: Role of BDNF in synaptic growth 
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Cortical regions where the BDNF is tropic are associated with memory 
and emotion like the hippocampus, cingulated gyrus and the prefrontal region. 
Positron Emission Tomography scan findings associated with depression are 
i) reduced activation of nucleus accumbens 
ii) diminished activity in neocortical and prefrontal cortex. 
iii) reduction in hippocampal size. 
All these correlate with BDNF deficiency. 
On the contrary the relationship between BDNF and depression is not 
consistent. BDNF Knockout animal models are not always associated with 
depressive behaviour. BDNF injected directly in to the animal’s ventricle 
increases depressive symptoms in certain animal models. The suggested 
explanation for these varied findings could be due to polymorphisms among 
BDNF. 
Psychosocial Theories 
Cognitive Behaviour Theory17 
Depression arises from cognitive maladjustment. Cognitive deregulation 
gives rise to misinterpreted thoughts and judgments. The severity of depression is 
directly proportional to degree of negative thought. Cognitive behaviour therapy 
is based on the helplessness-hopelessness ideology of cognitive theory. 
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Psychodynamic theory of depression 
According to Sigmund Freud, a person must successfully resolve early 
developmental conflicts in order to overcome depression and achieve mental 
health. Mental illness is a failure to resolve this conflict. 
 
Fig 5: Pathogenesis of depression 
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Apart from the biological and psychosocial theories the risk factors 
associated with depression are 18 
o Age- Peak age of onset is second to fourth decade. 
o Early parental death - Conceivable association 
o Genetics - More common in monozygotic twins than dizygotic 
twins; common genetic disorder involving the serotonin system. 
o Family history –When positive family history present there is 1.5 to 
3 times increased risk. 
o Marital status -Separated or divorced persons incidence is higher 
-In married males the incidence is lower 
-In married females the incidence is higher 
o Negative life events – Increased association 
o Personality –Anxious, compulsive, impulsive personalities are 
more prone. 
o Physical illness- Both in neurological and non neurological illness 
the incidence is increased. 
o Postpartum- An increased risk in the first 6-months 
o Sex- Major Depression is two times common in women 
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Fig 6: Integrated etiological model 
 Secondary causes of depression 
o Drugs 
o Substance abuse 
o Medical conditions 
 Drugs 
o Adrenocorticotropic hormone 
o Clonidine 
o Diuretics 
o Guanethidine 
o Interferon beta 
GENETIC
NEUROTICISM
STRESSFUL
EVENTS
PREVIOUS EPISODES
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o Isotreinoin 
o Hydralazine 
o Methyl dopa 
o Oral contraceptives 
o Reserpine 
o Propronolol 
Substance abuse 
o Alcoholism 
o Marijuana abuse 
o Nicotine dependence 
o Opiate abuse and dependence 
o Psychostimulants  abuse and dependence (e.g., cocaine) 
Medical conditions19 
 Endocrine abnormalities 
 Hypothyroidism 
 Addison’s disease 
 Deficiency states 
 Severe anemia 
 Wernicke encephalopathy 
 Infections 
 AIDS 
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 Tuberculosis 
 Sexually transmitted disease 
 Metabolic disorders 
 Hypokalemia 
 Hyponatremia 
 Hepatic encephalopathy 
 Cardiovascular disease 
 Hypertension 
 Congestive heart failure 
 Myocardial infarction 
 Neurologic disorders 
 Alzheimer’s disease 
 Epilepsy 
 Huntington disease 
 Multiple sclerosis 
 Pain 
 Post stroke 
 Parkinson’s disease 
 Malignancy 
Mood Disorder Classification: 
Based on Diagnostic and Statistical Manual of Mental Disorders-V (DSM-
V) mood disorders are classified as follows 
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A. Depressive Disorders 
1. Major Depressive Disorder, Single Episode 
2. Recurrent Major Depressive Disorder, 
3. Dysthymia 
4. Depressive Disorder Not Otherwise Specified 
B. Bipolar Disorders 
1. Bipolar Disorder, Single Episode 
2. Recurrent Bipolar Disorder 
3. Cyclothymia 
4. Bipolar Disorder Not Otherwise Specified 
C.  Premenstrual Dysphoric Disorder (PMDD) 
    (Included in DSM V.) 
D. Secondary Mood Disorder Due to Non psychiatric Medical Condition 
E. Substance-Induced Mood Disorder 
Clinical symptoms 
 Mood 
Depression is characterized by sad mood, loss of pleasure or 
interest in day to day activities, social withdrawal, and decreased 
occupational performance. 
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 Depressive ideation 
Hopelessness, helplessness, worthlessness giving rise to slowed 
thinking, pessimistic ideas and suicidal ideation. Severe cases are 
characterized by delusions of nihilism. 
 Psychomotor activity 
Decreased energy, monotonous voice, agitation, restlessness, anxiety, 
irritability and frustration 
 Physical symptoms 
Fatigue, chronic body aches, 
 Biological functions 
Excess or decreased sleep, loss of or excess appetite with weight 
modifications accordingly, and loss of libido. These changes in biological 
function is called somatic syndrome. 
 Suicidal risk 
Suicidal risk is found to be the most consistent symptom of 
depression, especially in male loners. It will be present throughout the 
depressive episode. Borderline personality disorders increase the risk of 
suicide. Mostly completed suicide is not preceded by suicidal attempts. So 
every patient irrespective of their previous episode is at risk of 
endangering their life. 
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Other syndromes of depression 20 
 Involutional melancholia 
Occur in old age associated with excess somatic symptoms, 
hallucination and delusion. 
 Mixed anxiety- depressive disorder 
More common, neither fit into depression, nor into anxiety 
 Masked depression 
Depression is masked by somatic symptoms like chronic pain, 
paresthesia, and alcohol abuse 
 Depressive equivalents 
Agoraphobia, panic attacks, hysteria, obsessive compulsive 
disorder. 
 Double depression 
Major depressive episode superimposed on dysthymia 
 Seasonal mood disorder 
Bipolar or unipolar depression tends to occur in the same season. 
Diagnosis of Depression21 
For the diagnosis of major depressive episode five of the above mentioned 
symptoms must be present; out of this one must be sad mood and loss of pleasure 
and the symptoms must persist for two weeks. 
The symptoms due to stressful event should be ruled out. 
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There should not be a manic or hypomanic episode. 
After diagnosing major depressive illness it has to be categorized based on the  
i) Severity of symptoms 
 Mild 
 Moderate 
 Severe 
ii) Recurrent or single episode: 
When the episodes are separated by a period of two months it is 
recurrent episode. Otherwise considered as single episode 
iii) Partial or in full remission 
iv) Specifiers (associated with) 
with anxiety 
with catatonia 
with atypical features 
with peripartum onset 
with seasonal pattern 
mood -congruent psychotic features 
mood -in congruent psychotic features 
So according to DSMV the diagnosis of depression should be mentioned with 
o Grade of severity 
o Order of episode 
o Currently in remission or not 
o Associated Specifiers. 
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Apart from the baseline haematological, renal and hepatic parameters, 
other adjuvant investigations are 
Cortisol level assay 
Thyroid level 
Sleep pattern 
Monoamine metabolite turnover 
Scales for Depression 
A depression rating scale is a psychiatric measuring instrument having 
descriptive words and phrases that indicate the severity of symptoms for a time 
period.  It is used to find the severity of depression, response to treatment and 
assess remission. Numerous scales are there but the important ones are 
1) Hamilton Depression Rating Scale 
It is the commonly used scale. In 1960, Max Hamilton designed a rating 
scale. It contains 17 questions and according to the severity each question is 
given a score from 0 to 4. 22 
2) Montgomery-Asberg Depression Rating Scale 
It is a questionnaire containing 10 items to be completed by researchers to 
assess the effects of drug therapy. It is a better scale for differentiating responders 
and non responders than the Hamilton Depression Rating Scale 23. 
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3) Raskin Depression Rating Scale 
It rates severity of the symptoms in three areas: verbal reports, behaviour, 
and secondary symptoms of depression. 
THERAPY 
Pharmacotherapy forms the main mode of management. Non 
pharmacological management like cognitive behaviour therapy acts 
synergistically with pharmacotherapy. Electro Convulsive Therapy (ECT) is used 
in severe depression with suicidal ideations for immediate effects. 
 
Pharmacotherapy is the common and most productive intervention in the 
treatment of MDD, which helps to attain remission and also prevents 
reoccurrence. Among the available drugs, SSRIs and SNRIs are commonly used. 
They belong to second generation antidepressant drugs. TCAs and MAOIs of 
first generation are reserved for resistant cases, and not preferred as first line 
because of their adverse effects. 
 
THERAPY 
Pharmacological
Non 
pharmacological
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CLASSIFICATION OF ANTIDEPRESSANTS24 
I. Tricyclic antidepressants (TCAs) 
i)  Nonselective reuptake inhibition of both NA & 5HT 
 Amitryptiline 
 Clomipramine 
 Doxepin 
 Dothiepin 
 Imipramine 
 Trimipramine 
ii) Relatively specific NA reuptake inhibition 
 Amoxapine 
 Desipramine 
 Lofepramine 
 Norclomipramine 
 Nortriptiline 
 nordoxepin 
 Maprotiline 
 Reboxetine 
II. Selective Serotonin Reuptake Inhibitors (SSRIs) 
 Citalopram 
 Escitalopram 
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 Fluoxetine 
 Fluvoxamine 
 Paroxetine 
 Sertraline 
III. Serotonin and Noradrenalin reuptake inhibitors 
 Desvenlafaxine 
 Duloxetine 
 Levomilnacipram 
 Milnacipram 
 Venlafaxine 
IV   Noradrenaline Reuptake Inhibitors 
 Reboxetine 
V    Monoamine Receptor Antagonists 
 Mirtazapine 
 Trazodone, 
 Mianserin 
VI   Monoamine Oxidase Inhibitors 
i)  Irreversible, non-competitive inhibitors 
o Isocarboxazid 
o Phenelzine, 
o Tranylcypromine 
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ii) Reversible MAO-A-selective inhibitors (RIMA) 
o Belfoxatone 
o Brofarmine 
o Clorgyline 
o Moclobemide 
o Pirilindole 
o Toloxatone 
VII    Others 
o Bupropion 
Non Pharmacological Treatments 
1. Psychotherapies 
2. Brain stimulation techniques 
1. PSYCHOTHERAPIES 
 Cognitive Behavior Therapy 
Cognitive behavior is the first line therapy in managing mild to moderate 
depression. In severe depression, CBT should be combined with 
pharmacotherapy for effectiveness. Its main objective is to correct the 
negative ideations. 
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 Inter Personal Therapy (IPT) 
 Inter personal therapy helps to improve the social functioning of the 
patient by exploring stressors like interpersonal disputes, transitions, skill 
deficit, and isolation. 
Educate the family for the purpose of treatment compliance. Family 
focused therapy with sessions of psychoeducation, communication training and 
problem solving skill training for the family members to achieve better treatment 
compliance. 
2. BRAIN STIMULATION TECHNIQUES 25 
 Electro- Convulsive Therapy (ECT) 
Electro- convulsive therapy is one of the earliest treatments and is 
still the most effective in treating severe depression, but for a short span 
only. It should always be given along with antidepressants. It is preferred 
in patients with suicidal tendency. Bilateral ECT is more effective than 
unilateral ECT. 
 Deep brain stimulation 
Chronic white matter stimulation along the cingulated region in 
resistant cases 
 Vagus Nerve Stimulation 
An electrical device is implanted in the chest wall in the 
subcutaneous plane which stimulates the cortex through the left cervical 
vagus. Federal Drug Agency (FDA) approved this technique for resistant 
depression and epilepsy. 
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 Transcranial Magnetic Stimulation (TMS) 
It’s a non invasive method of applying electrical stimulus through 
the scalp. Left frontal TMS gives some benefit. 
 Light therapy 
Light therapy is a treatment for seasonal affective disorder. It 
relieves irritability associated with depression. Less effective in non 
seasonal depression 
Non responders                                                                                                                            
 As depression is a heterogeneous disorder, there are various reasons for 
non responding. The common non responders are old age, patient with limited 
economic and interpersonal resources, low quality of life, chronic depression, 
poor social and family setup, noncompliance and vascular depression. 
 Diagnosis must be reassessed 
 Hypothyroidism if present should be corrected 
 Whether the patient had taken drugs for a sufficient  period, so that the 
antidepressants would have their full effect should be assessed . 
The treatment options for non responders are26 
o optimization of antidepressants dose 
o switching to other antidepressants 
o combination of antidepressants 
o augmentation strategies 
o somatic therapies 
o integrated approach 
o adjunctive approach 
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DRUGS USED IN DEPRESSION 
Selective 5-hydroxytryptamine reuptake inhibitors 
SSRIs are the commonly used anti depressant drugs. They are very much 
effective in treating major depressive illness. TCAs remained the mainstay of 
drug therapy of depression for many years. To overcome the adverse affects of 
TCAs due to blockade of receptors other than serotonin and adrenaline there was 
a continuous search for a better compound. With methodological screening 
SSRIs were introduced based on the structure of TCAs. Though SSRIs have a 
single therapeutic profile of blocking the Serotonin reuptake transporter (SERT), 
they are chemically diverse compounds.27 
 
Fig 7: Structure of various SSRI 
31 
 
Fluoxetine 
The first introduced SSRI was zimelidine, but it was associated with 
Guillain–Barre´ syndrome. Second one was fluvoxamine, then came fluoxetine. It 
is the commonly prescribed SSRI. In this study it was used as the standard drug. 
The primary target of SSRI is SERT. It differs from other SSRIs in its secondary 
pharmacological characteristics. 
 
 
 
 
 
 
 
 
 
 
Fig 8: The primary and secondary pharmacological characters of SSRIs in 
common and the primary and secondary pharmacological characters of 
Fluoxetine 
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Mechanism of SSRI28 
SSRI act by blocking the pre synaptic serotonin-auto receptor. This block 
will resonate in the pre synaptic somotodentritic region near cell body, resulting 
in increased serotonin in the region, which will provide the therapeutic 
effectiveness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Decreased serotonin level in both  
somotodentritic region and in synapse 
 region. 
Ineffective conversion of signal 
transduction to gene transcription  
Up regulation of receptors 
Depression  
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Cascade of therapeutic effectiveness        
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As in the above mentioned cascade of pharmacological events, acute rise 
in serotonin level in synapse immediately after the blockade of SERT is 
responsible for the adverse events. Increased serotonin release that happens after 
the desensitization of 5HT1A, due to neuronal release is responsible for its 
therapeutic effectiveness. The time taken for this process explains the therapeutic 
lag that happens with SSRI. The therapeutic effect correlates with the 5HT1A 
receptor desensitisation and down regulation. 
 
Fig 9: Effect of acute and chronic blockade of SERT on 5-HT release 
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Pharmacokinetics 
Fluoxetine is available in oral formulation; well absorbed and 
bioavailability is around 70%.  It is a prodrug; the active moiety is norfluoxetine. 
It is highly protein bound and has large volume of distribution. The elimination 
plasma half life of nor fluoxetine is around 180 hours which is three times more 
than the half life of fluoxetine. So at any given time, the plasma concentration of 
nor fluoxetine is always higher than that of fluoxetine. The active metabolite is 
the reason behind, fluoxetine being the SSRI with longest half life. The 
metabolites of fluoxetine are excreted through kidney. 
Cytochrome p 450 (CYP) metabolism and interactions: 
Fluoxetine is a substrate of CYP 2D6. It is also an inhibitor of CYP 2D6 
along with CYP1A and CYP2C19 inhibition. Due to CYP inhibition it interferes 
with the metabolism of drugs like 
 Tricyclic antidepressants 
 Antipsychotics (thioridazine , haloperidol) 
 Opioids (codiene, oxycodiene methadone) 
 Beta blockers. 
Polymorphism of CYP 2D6 among various populations has to be 
considered with all of the above mentioned drugs. With MAO inhibitors, 
fluoxetine produces a dreadful condition called serotonin syndrome. It is due to 
increased serotonin and is characterized by diaphoresis, tremor, autonomic 
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instability, cardiovascular collapse, seizure and coma. To avert this as fluoxetine 
has a long half life; it has to be stopped 4 to 5 weeks before starting MAO 
inhibitors. 
Uses 
As antidepressants 
The therapeutic effect in depression is because of 5HT1A receptor 
activity. It is the commonly used drug for major depressive illness. The target 
dose of fluoxetine in depressive disorder is 20 mg/day, though it may be raised 
up to 80mg/day, many patients respond to the routine dose itself. In pregnancy 
the risk of untreated depression overweighs the risk to the fetus. 
Other uses 
 Anti bulimic profile: 
Higher dose is needed; effect is relatively quick and it is due to 5HT2C 
activity. They reduce the binge purge cycle. Fluoxetine is the SSRI of choice. 
It is arguably the most anorexigenic of the SSRIs and with a specific 
indication for bulimia, is also the only SSRI with direct 5-HT2C agonist 
activity in addition to its 5-HT reuptake blocking properties. 
 Premenstrual Dysphoric Disorder 
SSRIs are effective in reducing the symptoms of PMDD. The dosing 
strategies with SSRIs include once daily and intermittent dosing (last two 
weeks of the menstrual cycle) 29 
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 Obsessive Compulsive Disorder.(OCD) 
In addition to CBT which has efficacy per se of 50-70%, SSRIs when 
added can prevent the relapse in OCD. 
 Generalized anxiety disorder and panic social anxiety disorder 
Similar to therapeutic lag in anti depressant effect, SSRIs take two to 
three weeks to act in this disorder. The dose is 5–10 mg/day. 
 Post Traumatic Stress Disorder: 
There is no complete recovery with SSRI, but it decreases the 
symptoms and provides functional improvement. In responders, the period of 
treatment is 6months to one year in acute episodes and one to two years in 
chronic episode. 
ADVERSE EFFECTS 
The adverse effects are less than TCAs, because of selective SSRI action. 
 
 
 
 
 
Fig 10: Illustrating the receptor specificity of SSRI 
Vs 
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SSRIs increase serotonin level in both desirable and undesirable pathway. 
Serotonin action in the undesirable pathway and receptor is responsible for its 
adverse reaction. With SSRI the adverse effects happens faster than the 
therapeutic effect, as it is due increase in post synaptic serotonin instantly after 
SERT blockade. 
The common adverse effects are 
Gastrointestinal complaints 
CNS disturbances 
Sexual dysfunction. 
 Gastrointestinal complaints 
Within 1 -2 hours of ingestion they induce gut irritation and produce 
nausea which is a common complaint. So it is advised to be taken with food. 
Nausea in SSRI may also be due to stimulation of 5-HT3C receptors in the 
chemoreceptor trigger zone (CTZ).  CTZ mediated nausea needs dosage titration. 
Incidence of diarrhea is around15-20%. 
 CNS disturbances 
The frequent symptom is sleep disturbance; fluoxetine is the most 
common SSRI producing this symptom. So it should be taken at morning after 
breakfast. Other side effects are sedation, numbness and in few cases 
extrapyramidal side effects. 
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 Sexual dysfunction. 
Incidence of sexual dysfunction is around 30% to 50%; more common 
among men, but in severity it is worse in females. The major complaint is 
delayed orgasm, though it happens with all SSRI more common with paroxetine 
and fluoxetine 30. 
 Other adverse events 
Dry mouth and headache occur with SSRI and, although rare some 
somatic complaints like bruxism, sweating, few incidence of dilutional 
hyponatremia are prevalent in the general population and on chronic use it 
produces weight gain. 
Withdrawal 
Because of long half life there is no need for slow tapering as with other 
SSRIs. 
Other Antidepressants 
 Tricyclic antidepressants 
Before SSRIs, Tricyclic antidepressants were the commonly used drugs. 
Though therapeutic efficacy is similar to SSRIs, they are drugs having narrow 
therapeutic index so not preferred over SSRIs. The acute toxicities of TCAs are 
hypotension, respiratory depression, cardio toxicities like prolonged QT and 
broad QRS .The usual adverse effects are sedation, hypotension, weight gain, 
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sexual dysfunction, convulsion, anticholinergic effects, and hypersensitive 
reaction. Other than depression it is used in wide range of disorders like OCD, 
anxiety, phobias, attention deficit hyperactive disorder, nocturnal enuresis, 
migraine, psychosomatic disorder. 
Serotonin norepinephrine reuptake inhibitors (SNRIS) 
SNRIs are chemically different from each other. They block both 
Serotonin and Nor epinephrine transporters, similar in efficacy when compared 
with SSRIs, but with short half life. In adverse effects they are very similar to 
SSRIs. They exhibit dose dependent increase in efficacy due to weak 
Norepinephrine Reuptake Inhibition. Adverse effects are due to augmented 
adrenoceptors activation; they are insomnia, sexual dysfunction, headache, dry 
mouth, dizziness, sweating and loss of appetite. 
Noradrenaline uptake inhibitors 
Reboxetine and atomoxetine are the drugs that are highly selective for 
noradrenaline. Their efficacy is less than the TCAs. Atomoxetine is used in 
attention deficit hyperactivity disorder. 
5 HT receptor modulators 
Trazodone and nefazodone are the drugs. The activity is due to 5-HT2A 
receptor blockade. Nefazodone is also a weak inhibitor of both SERT and Nor 
epinephrine transporter (NET). Trazodone has an additional  α blocking property. 
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Monoamine oxidase inhibitors 
First introduced antidepressant, but it is now used only in resistant cases. 
Non specific MAOIs are not used now because of adverse events associated with 
drug and food interaction.  Specific inhibitors are introduced. MAO-B inhibitors 
do not have any antidepressants effect at doses that are precise for MAO-B 
inhibition. New class of agents- RIMA like Moclobemide is now used as 
antidepressants. 
Melatonin agonist 
The drug is Agomelatine. It act as an agonist at receptors MT1 and MT2 
.It has a short plasma half-life. It is used in severe depression; it works by 
regulating the circadian rhythm which is often disturbed in depression. 
CHOICE OF ANTIDEPRESSANTS 
Most of the antidepressants are equal in efficacy against Major Depressive 
Disorder, so it is tough to pinpoint one antidepressant to be consistently better 
than the other. Thus, the choice will be based on cost, adverse effects, 
availability, patient’s response to therapy, drug interactions, age, and medical 
issues. 
SSRIs are the preferred choice due to their efficacy, safety, tolerability 
profile. There is no need for dose titration. Other drugs like SNRIs, mirtazapine, 
bupropion also provide a choice as first-line management for MDD. 
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Individual drug of choice for a patient is going to be tailor made for that 
particular patient. If the patient complaints of insomnia and sexual dysfunction 
due to SSRIs then mirtazapine serves as a choice as it promote sedation and no 
sexual dysfunction. In elderly due to anticholenergic side effects TCAs are not 
commonly preferred. Moreover TCAs and MAOIs are now regarded as second 
and third choice in the management of MDD. 
COURSE OF TREATMENT 
The purposes of the treatment is to cutback the acute symptoms, aid the 
patient to return to functioning life and to prevent consequent episodes. The 
course of the disease used to be, single cycle of MDD if untreated last for 6–14 
months, in few patients it may last even longer. Once pharmacotherapy is 
initiated it will take 3 to 4 weeks for the drug to act. So for any antidepressant we 
have to give a trial period of 8 -12 weeks, before judging the therapeutic efficacy. 
This therapeutic lag of antidepressants is due to the time taken to adaptive 
changes in the neuronal plasticity that happens secondary to increase in synaptic 
neurotransmission. The objectives of the treatment are31 
1) Remission –decrease in symptoms 
2) The continuation phase for 4 to 9 months has to be given in the post 
remission period. The target of this phase is to get rid of the residual 
symptoms and prevention of relapse and 
3) The maintenance phase is for minimum of 12 to 36 months in which the 
target is to counter reoccurrence. 
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Fig 11: Course of depression 
Remission - Absence of symptoms 
Relapse  - Return of symptoms not over a period of 6 months of remission 
Recurrence  - A separate episode of depression 
The span of antidepressant therapy depends upon the risk of recurrence. 
The hazard of recurrence increases proportionate to the number of previous 
episodes. For persons who are at increased risk for reoccurrence, such as 
i) Patient less than 40 years with two or further previous episodes and 
ii) Irrespective of age with three or further previous episodes 
Investigators recommend lifelong maintenance therapy. 
. 
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Fig 12: Algorithm of MDD treatment 
Lag in antidepressant effect and the importance of compliance should be 
well informed to the patient, family members and friends. 
Newer targets 
Vilazodone and vortioxetine, are recently marketed drugs for MDD, they 
target both 5-HT1A receptors and the SERT in their action. Thus they refine and 
expand the monoaminergic mechanisms32. 
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In addition based on various biological hallmarks of the disease and 
efficacy of pharmacological interventions, different hypotheses of depression are 
being put forward in translational and clinical researches. These targets are 
beyond SSRIs and SNRIs. They are multitarget or multimodal approaches that 
have additive or synergistic effects on selected biological pathway. Some 
examples are 
 Neurokinin system-particularly Nk1 antagonists. 
Neurotensin 
Chole-cystokinin, 
 Cannabinoid system 
Anandamide 
 Glutamate system 
NMDA receptor antagonist 
AMPA modulators 
 Opioid syatem 
κ opioid receptor Antagonists 
 Cognitive enhancers 
Ampakines 
Nicotinic cholinergic receptor 
Erythropoietin 
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 GABA system 
GABA B antagonist. 
 Others 
GRII cortisol receptor antagonists, 
Melanocyte inhibiting factor (MIF-1) analogues 
 Miscellaneous agents 
Methylfolate, 
Oestrogen 
Omega-3 Fatty Acids 
S-Adenosyl Methionine 
Folic Acid 
 Plant derived drugs 
Hyperforin, 
Kava, 
Ginkgo biloba, 
Curcuma longa, 
Rosmarinus  officinalis 
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STATINS 
Statins are commonly used cholesterol lowering agent. They are the most 
effective drug for dyslipidemia. The precursor of stain was biosynthesised from 
Penicillium citrinium. Mevastatin was the first Statin with demonstrable 
therapeutic potential. Then from Aspergillus terreus, lovastatin was derived33. 
Now the available statins are 
Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin and 
Simvastatin. 
 
Fig 13: Structure of Statins 
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Simvastatin and pravastain are derived from lovastatin. The synthetic ones 
are atrovastatin, rosuvastatin, fluvastatin and pitavastatin. All the synthetic 
compounds contain fluorine. 
Based on their potency of Low Density Lipoprotein (LDL) lowering effect 
Statins in descending order 
Pitavastatin 
Rosuvastatin 
Atorvastatin 
Lovastatin 
Pravastatin 
Simvastatin 
Fluvastatin . 
The potency of Statins is dose dependent34. 
Mechanism of action 
The mechanism of action of Statins is due to the inhibition of the enzyme 
3-Hydroxy- 3 Methyl Glutaryl Coenzyme A. (HMG CO-A) Reductase. This 
enzyme is involved with cholesterol biosynthesis. Statins act as a competitive 
inhibitor of this enzyme. It decreases the biosynthesis of cholesterol35. 
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Fig 14: HMGCo-A has structural similarity to active form of Lovastatin 
Acetyl-CoA + Acetoacetyl-CoA 
HMG-CoA 
STATIN HMG-CoA 
REDUCTASE 
Mevalonate 
Cholesterol 
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The fascinating thing in the cholesterol synthesis is the intermediate 
substances like ubiquinone and dolichol, which are produced in this cycle in 
addition to cholesterol. These intermediates are isoprenoids. They are involved in 
a reaction called Prenylation. It is a lipidic modification of cellular proteins 
during the post translational period. 
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Farnesyl and  Geranylgeranyl  isoprenoids which are adjuvant products of  
the cholesterol synthesis pathway irreversibly bind themselves to  Ras and Ras- 
associated  GTP-binding proteins, Rho proteins and Rab proteins and prenylate 
them36. 
Competitive inhibition of HMG-CoA reductase by statins not only 
decrease cholesterol synthesis but also decreases these isoprenoids that are 
required for prenylation. A study by Bassam R. Ali et.al37 demonstrated the 
reversible inhibition of prenylation of signaling proteins by Mevastatin. This 
supplementary mechanism of statins are accountable for their various pleiotropic 
effects 
Statins have the following pleiotropic effects38 
 Better  endothelial activity 
 Decreases the vascular inflammation 
 Improved  ischemic tissue neovascularisation 
 Reduced platelet aggregation 
 Atherosclerotic plaque stabilization 
 Increased endothelial progenitor cells 
 Increased fibrinolysis 
 Antithrombotic activity 
 Immunosuppressant 
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 Protection against infection 
 Inhibition of migration of germ cell during embryogenesis. 
 Anti cancer property 
Neovascularisation 
 Statins increase the endothelial progenitor cells39. 
 Increase their migratory capacity 
 Alter their adhesiveness and 
 Enhance their mobility towards injured site thereby augment the 
neovascularisation of ischemic tissue. 
Effect on Endothelium 
In hypercholesterolemia the endothelium mediated vasodilatation is 
affected. This is due to impaired nitric oxide (NO) production. Statins increase 
the NO production by the endothelium. Statins induced NO synthesis is by 
1) blockade of LDL induced down regulation of  endothelial Nitric Oxide 
Synthase (eNOS) 
2) Mechanism irrespective of its cholesterol Lowering effect. 
 Statins suppress the Rho/Rho signaling activity which decreases the 
eNOS mRNA stability 
 It decreases caveolin-1 expression in endothelium, which 
disintegrates the eNOs and hence increases NO. 
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Anti Inflammatory Effect 
 
 
 
 
 
 
 
 
 
Statins as Immuomodulator40 
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Effect on Plaque Stability41 
Statins ensure plaque stability by two mechanisms: 
i) Reduction in macrophage accumulation at plaque site. 
ii) Reduction in Matrix metalloproteinase (MMP) secretion thereby 
reducing the plaque rupture. 
Anti thrombotic activity42. 
 
 
 
 
 
 
 
 
Effect on Lipoprotein Oxidation 
Oxidized LDL is proinflammatory. Anti-oxidant activity of statin  is due to 
 Decreased  Nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase43 
 Decreaed superoxide formation 
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Fibrinogen 
cleavage 
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Factor XIII 
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Activation 
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clotting 
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 Decreased  oxygen free radical 
 Neutrophil oxidative burst 
Effect on Fibrosis 
Statins can decrease fibrosis by inhibiting the angiotensin-mediated 
growth factor production for the connective tissue growth. MMP expression is 
also reduced. 
Anti Cancer Property 44 
In the cell cycle, statins prevent the progression of G1-S Phase resulting in 
anti proliferative effect. Experiments showed that this anti cancer effect is more 
attributed to free geranylgeraniol rather than farnesylated proteins inhibition. 
Other Effects: 
Statins increase the bone growth factor- Bone morphogenic protein 
(BMP)-2. Hence preventing osteoporotic changes in animal model45. They have 
antiepileptic activity by blocking the NMDA pathway 
Pharmacokinetics of Statins 46 
Lovastatin and Simvastatin are prodrugs. All other statins are active drugs. 
The above mentioned prodrugs are administered as lactones. Their active 
metabolite is beta -hydroxy acid. Pravastatin, Fluvastatin are sodium salts; 
Atrovastatin is a calcium salt of active beta hydroxy acid. 
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They are fat soluble substances; have high absorption when combined 
with food except pravastatin. These substances have enormous first pass 
metabolism, so the systemic availability is around 5-20%. Cholesterol lowering 
effect happens within one to two weeks of therapy. Brain is the cholesterol rich 
organ in the body. Statins have high CNS permeability. The hypolipidaemic 
effect of Statins would not alter the cell membrane’s cholesterol homeostasis in 
the central nervous system. Atrovastatin and rosuvastatin are long acting; all 
other Statins have half life around 1-4 hours. Atrovastatin metabolites are active 
inhibitors of HMG Co-A reductase, all statins are excreted by liver. 
Adverse Effects47: 
 Myopathy: 
Myopathy is a clinically significant adverse effect of statins. The 
incidence is very low and it is around 0.1% to 1%. It happens with all the statins. 
Creatine phosphokinase (CPK) monitoring is warranted when patient complaints 
of muscle weakness, soreness. When myopathy happen it settles on withdrawl of 
the drug, we can rechallange with other statins. 
 Hepatotoxicity: 
It is dose related and characterised by increase in transaminase enzyme. 
The incidence is inconsistent, and very rare at therapeutic doses. So the protocol 
is to have a base line value of alanine aminotransferase, then once in three 
58 
 
months in the initial period and once in a year or every six months thereafter. 
Incidence increases in patient with underlying liver pathology. 
Other minor adverse reactions that fade out on chronic usage are 
headache, gastrointestinal disturbance, peripheral neuropathy, lupus like 
syndrome. 
Drug interaction and Statins 
Lovastatin, Simvastatin, and Atrovastatin are substrate of CYP3A4. 
Fluvastatin, Rosuvastatin are substrate of CYP2C9.  Enzyme inducers will reduce 
the plasma concentration of statins and enzyme inhibitors like antifungals, 
macrolide, antibiotics, protease inhibitors, nefazodone like antidepressants 
increase the concentration of statins thereby the risk of myopathy. 
Statins are contraindicated in pregnancy, because their effect on foetal 
development is uncertain48. It is safe in children above 8 years of age. 
Therapeutic Use 
 Common therapeutic indication of statins is dyslipidaemia for primary and 
secondary prevention of coronary events. 
Due to its pleiotropic effect it is used in 
 Cardio Vascular Diseases (CVD) 
o Statins  decrease the risk of cardio vascular diseases in patient with 
metabolic syndrome 
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o it decreases the incidence of CVD in apparently normal old people 
irrespective of hyperlipidemia and metabolic syndrome49 
o In primary hypertension in children, the use of statin decreases the 
incidence of atrial fibrillation probably due to its anti inflammatory 
property50. 
 Preoperatively used in coronary revascularization surgery. 
Percutaneous coronary intervention is associated with myonecrosis due 
to platelet aggregation and distal embolisation in response to 
inflammation. Statin decrease it. 
 Irrespective of the cholesterol level it is used in patient of >40 years of 
age with type II diabetes51 
 In thrombo ischemic attack and stroke, statins decrease the risk of 
recurrence 52 
 Renal artery stenosis & Acute limb ischemia 
Statins and Depression 
Statins and depression has to be viewed in the context of 
 Cholesterol level and depression 
 Pleiotropic effect of statins and depression 
Cholesterol level and Depression 
Though the literature is flooded with information about the relationship 
between cholesterol and depression, it is still elusive. The relationship between 
60 
 
cholesterol and depression is two faceted.  Some studies demonstrate that lower 
blood cholesterol level is associated with depression. Series of case reports are 
published about statins being associated with cognitive impairment, the rationale 
provided were, 
 Low esterification of cholesterol is associated with alterations in the 
composition of cholesterol and phospholipids on the cell membrane. It 
results in altered receptor density, neurotransmitter exocytosis, and 
signal transduction. 
 There is association between, low level ω3 fatty acid and increased ω6 / 
ω3 ratio with depression53. 
 Cholesterol is essential for the synthesis of neurosteroids. Long term 
exposure of statins to the neurons of the brain endangers the formation 
of synapses; particularly in the hippocampus which predisposes to major 
depressive illness. 
Metanalysis has proved statins are not associated with any cognitive 
impairment54. Many studies show that there is no correlation between lower 
cholesterol level by statins and depression. Even some studies proved that high 
cholesterol levels are associated with treatment resistant depression. Also it needs 
mention that the use of statins for cardiovascular diseases like myocardial 
infarction (MI) showed decreased scores of post MI depression in those patients. 
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Pleiotropic Effect of Statins and Depression 
Inflammation, free radical injury and vascular pathology are the 
etiological factors for depression. Pleiotropic effect of Statins combat all this. 
Vascular depression and statin 
Vascular depression is most common in geriatric age. Any pathology in 
the brain vasculature can predispose as well as precipitate depression. 
Vascular depression is characterised by white matter hyper Intense lesion 
on imaging. It is quite resistant to treatment with conventional anti depressants 
 
In this study statins were evaluated for its anti depressant property with 
fluoxetine as standard by tail suspension method. 
  
Vascular
damage 
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perfusion
Inflammation
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damage 
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Evaluation Methods for Antidepressants55 
Most of the antidepressant drugs that we use today are generated based on 
the monoamine hypothesis. The foremost one is non-selective MAOIs. They are 
coupled with dangerous food and drug interactions. With TCAs the disadvantage 
is its additional alpha receptor blocking and narrow therapeutic index which 
produce life threatening toxicities. To overcome these drawbacks, SSRIs were 
introduced. They are better tolerable and safer than TCAs. They have side effects 
like insomnia and sexual dysfunction which makes the drug less compliant. There 
is always a search for antidepressant which are safe and efficacious and with 
fewer adverse effects. 
In evaluating anti depressant activity through animal studies, the major 
downside is that the animal models cannot simulate major depressive illness as in 
human beings. So the principle behind the various screening models is comparing 
the new drug with already standardized anti depressant. There must be a 
correlation between the standardized antidepressant and the effect of test drug on 
the animal model. 
In vivo methods in animal are: 
1. Amphetamine potentiation 
2. Apomorphine antagonism 
3. Chronic social defeat stress 
4. Forced swim test 
5. Isolation induced hyperactivity 
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6. Learned helplessness test 
7. Muricidal behavior in rats 
8. Olfactory bulbectomy 
9. Postpartum depression models 
10. Reserpine induced hypothermia 
11. Resident intruder paradigms in rat 
12. Tail suspension test 
13. Water wheel model 
Of the above mentioned test, tail suspension method is based on the 
principle of behaviour despair model which was used in this study. Other test that 
are based on the same principle are 
Water wheel model 
Forced swim test 
WATER WHEEL MODEL 
It is based on the principle ‘behavioural despair activity’. Animal is forced 
to swim in a tank filled with water. A rotating wheel presents inside the tank fake 
itself as an option for escape. The animal tries it and due to their weight it again 
turns them to water. The animal becomes desperate and immobile when 
depressed. The antidepressants increase the number of attempts of escape; 
measured by number of rotation of the wheel. 
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FORCED SWIM TEST 
 In a restricted water tank, mice or rats are enforced to swim, with nil 
probability to escape. After an initial span of struggling, the animal develops a 
characteristic behaviour of immobility. Duration of immobility gets reduced with 
antidepressants. 
TAIL SUSPENSION TEST  
Tail suspension test is based on the principle of behavioral despair. It was 
first done by Steru et al. Reproducibility is more in this experiment if we use 
mice rather than rat. It is a very reliable and rapid method used in screening new 
antidepressants. When mouse is suspended in the box with its tail plastered with 
an adhesive tape, it cannot escape or hold on to nearby wall, ‘behavioral despair’ 
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is induced. The test is done for a period of 6 minutes. The mice will exhibit 
escape-oriented behavior. Due to desperation mice will be immobile for a while. 
The duration of immobility is noted for the whole 6 minutes. The immobility 
period is directly proportional to the degree of depression. This test is not suitable 
for MAO inhibitors. These animal models are best for drugs which are using 
serotonergic mechanism. This test can also be done using a computer assisted 
system. By this we can calculate the immobility, and activity of the mice in real 
time. 
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MATERIALS AND METHODS 
The current study, evaluated the anti- depressant activity of the 
pharmacological agent statin in adult male Swiss albino mice by tail suspension 
method. For the study, approval was obtained from Institutional Animal Ethical 
Committee of Madurai Medical College, Madurai. Dated 23.03.2017. 
Study Centre 
Institute of pharmacology, Madurai medical college, Madurai. 
DURATION 
Study period was 6 months since March 2017. 
NUMBER OF ANIMALS USED 
30 adult male albino mice of weight 25 -30 grams. 
DRUGS REQUIRED 
Standard group was treated with Capsule. Fluoxetine 20mg /kg 
Test groups were treated with various statins. 
Test I with Tablet Rosuvastatin 10 mg/kg 
Test II with Tablet Atrovastatin 10 mg/kg 
Test III with Tablet Simvastatin 10 mg/ kg 
Control group received Distilled water 
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Other materials required 
Weighing  machine 
Stirrers and beakers 
2ml syringes 
Stainless steel oral feeding tube 
Tail suspension box 
Plastic tubes 4 cms x1.5cms as climb stoppers 
Adhesive tapes 
Stop watch 
Digital camera 
Drugs 
Rosuvastatin 10mg, Atrovastatin 10 mg, Simvastatin 10mg tablets were 
used for test group I, II, and III respectively and at a dosage of 10mg/kg. They 
were dissolved in distilled water and given orally. Capsule. Fluoxetine was used 
on the standard group at a dosage of 20mg/kg, dissolved in distilled water and 
given by oral route. 
Procedure 
30 male Swiss albino mice were procured from our central animal house, 
Madurai Medical College, Madurai.  The animals were sheltered in a cage made 
of polypropylene and they were maintained at room temperature with 
a12hours:12hours light/dark cycle. They were provided with free access to food 
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and water throughout the day, and they had it ad libitum.  The experiment was 
conducted at their domicile itself. 
The principles of committee for the purpose of controlled supervision of 
experimentation on animals (CPCSEA) guidelines were followed since 
procurement to the follow up period, and throughout the study period the animals 
were handled by well trained personnel, with adequate care. 
The 30 animals were divided into 5 groups of 6 animals in each group. 
Group I served as control, group II served as standard, group III, group IV, group 
V served as test group. Drugs were administered orally, for a period of 14 days 
once daily in the morning as mentioned in the table below according to the group. 
Drug details of each category 
Group Study group TREATMENT 
I CONTROL Normal feed and Water+ Distilled water 
II STANDARD Normal feed and Water +  Cap. Fluoxetine 20 mg/kg orally 
III TEST -1 Normal feed and Water + Tab. Rosuvastatin 10 mg/kg orally 
IV TEST-2 Normal feed and Water + Tab. Atrovastatin  10 mg/kg orally 
V TEST-3 Normal feed and Water + Tab. Simvastatin 10 mg/kg orally 
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ORAL FEEDING TECHNIQUE 
Feeding tube used was a hypodermic needle made of stainless steel. It has 
a blunted tip, which is soldered with a small ball around it.  A two ml syringe 
which contained the drug to be administered was attached to the needle. Mouse 
was gently  grasped by the nape of neck , and secured in the left hand. The oral 
feeding tube was introduced in the inter dental space laterally. Then with a gentle 
rotatory movement it was advanced into the oesophagus. On reaching the desired 
level, the drug was pushed gently. 
Tail suspension test 
Tail suspension test was performed on day 7 and day 14 of the experiment, 
one hour after the drug administration. It was carried out for all the groups in the 
experiment such as the control, standard, test –I, test –II, test III in such a way 
that all the six animals belonging to a group were tested simultaneously. 
The tail suspension box is a rectangular chamber made of plywood painted 
in brown colour to provide the contrast.  The dimensions of the box were height 
55 cm width 90cm and depth 11.5 cm. It was divided in to six chambers by 
placing dividers, so that each chamber had a width of 15cm. There was a 
provision in the roof of each compartment to hang the mice.  The space in each 
compartment was adequate to prevent the mouse from getting into contact with 
the wall.  The distance between the floor and the tip of nose of the suspended 
mouse was around 20-25cms. A detachable tray was placed in the bottom of each 
compartment to collect the excreta. 
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Clear hollow cylindrical plastic tubes of dimension 4 cms x 1.5cms were  
introduced into the tail and used as climb stoppers. An adhesive tape of length 
17cm were cut for each mouse and at 2 cm from one end a mark was made. The 
2cm marked portion of the tape was applied to the tip of the tail leaving 2-3 mm 
free and it was adhered securely. It was done for all the six animals in a group 
consecutively .Care was taken so that the tape is strong enough to hold the 
mouse’s weight, and not too sticky while removing. The camera with a timer set 
up was positioned in a way so that the view of the tail suspension box was not 
obscured and the recording would not be interrupted. All the six mice in the 
group were suspended back to back by attaching the free end of the adhesive tape 
that measures 15 cm to the hook at the roof of all six compartments. 
Without any interruption for the next six minutes the immobility time was 
recorded using the camera that was already positioned. The recordings were 
71 
 
saved at the end of six minutes. The animals were taken off the chamber; the 
tapes were removed with proper care. They were placed back into their cage and 
observed for a week. 
TAIL SUSPENSION TEST –BEHAVIORAL ANALYSIS56 
Assessment of the behaviour of all animals was done from the video 
recordings.  Total observation period was six minutes. Immobility time was 
assessed. Important facet of this assessment was to differentiate between mobile 
and immobile state of the animal. Behaviours that were associated with escapism 
like all four limb movements, attempt to touch the side walls, shaking of the 
body, running like movements were considered as mobility. While small 
movements involving forelimb without any hind limb involvement, movements 
due to oscillatory movement of the tape because of momentum gained by 
previous motion of the animal were considered as immobility. We had used the 
whole period of six minutes for assessment, because in general in tail suspension 
test the mice tend to be immobile more during the early period of the test. The 
immobility period was recorded by this method in all the groups after the 
corresponding treatment, and the scores were analysed statistically. 
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RESULTS 
In this study the results of the tail suspension test of various groups are as 
follows: 
Tail suspension test for control group 
The control group received distilled water in addition to normal feed and 
water. Tail suspension test was conducted one hour after drug administration on 
day 7 and day 14 .The duration of immobility was recorded. The mean 
immobility period of all the six animals in the group was calculated.  It is 
expressed as Mean± S.D. The mean immobility period in seconds on day 7 and 
day 14 were 198.83 ± 14.95. and 194.33 ± 11.48 
Table 1: TST result for control group 
Day 
Control group immobility period in seconds 
Mean ±S.D. 
1 2 3 4 5 6 
Day 7 205 192 175 220 203 198 198.83 ± 14.95 
Day 14 181 211 187 202 199 186 194.33 ± 11.48 
 
  
73 
 
Tail suspension test for standard group 
The standard group received fluoxetin 20mg/kg in addition to normal feed 
and water. Tail suspension test was conducted one hour after drug therapy on day 
7 and day 14 .The duration of immobility was recorded. The mean immobility 
period of all the six animals in the group was calculated.  It is expressed as Mean 
± S.D. The mean immobility period in seconds on day 7 was 120.16 ± 19.06 and 
on day 14 it was 126.83 ± 13.4. 
Table 2: TST for standard group 
Day 
standard group immobility period in seconds 
Mean ±S.D. 
1 2 3 4 5 6 
Day 7 109 121 110 105 157 119 120.16±19.06 
Day 14 144 115 117 134 138 113 126.83 ± 13.4 
 
Tail suspension test for test group I 
The mice in the test group- I received tablet Rosuvastatin 10 mg/kg in 
addition to normal feed and water. Tail suspension test was conducted one hour 
after drug therapy  on day 7 and day 14, the duration of immobility was recorded. 
The mean immobility period of all the six animals in the group was calculated. It 
is expressed as Mean ± S.D. The mean immobility period in seconds on day 7 
was 131.83 ±25.76 and on day 14 it was 128.83 ± 12.57. 
74 
 
Table 3: TST result for test group I 
Day 
Test group- I immobility period in seconds 
Mean ±S.D. 
1 2 3 4 5 6 
Day 7 142 115 96 155 120 163 131.83±25.76 
Day 14 133 108 126 130 147 129 128.83 ± 12.57 
 
Tail suspension test result for test group II 
The mice in the test group-II received tablet Atrovastatin 10mg/kg in 
addition to normal feed and water. Tail suspension test was conducted one hour 
after drug therapy on day 7 and day 14. The duration of immobility was recorded. 
The mean immobility period of all the six animals in the group was calculated.  It 
is expressed as Mean± S.D. The mean immobility period in seconds on day 7 was 
141.5±15.69  and on day 14 it  was 145.5±11.11. 
Table 4: TST result for test group II 
Day 
Test group- II immobility period in seconds 
Mean ±S.D. 
1 2 3 4 5 6 
Day 7 144 118 162 132 154 139 141.5±15.69 
Day 14 136 142 155 147 161 132 145.5±11.11 
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Tail suspension test result for test group III 
The mice in the test group- III received Tablet. Simvastatin 10mg/kg,  in 
addition to normal feed and water. Tail suspension test was conducted one hour 
after drug therapy with on day 7 and day 14 .The duration of immobility was 
recorded. The mean immobility period of all the six animals in the group was 
calculated.  It is expressed as Mean ± S.D. The mean immobility period in 
seconds on day 7 was 138.33±16.71 and on day 14 it was 132.5±15.1 
Table 5: TST result for test group III 
Day 
Test group- III immobility period in seconds 
Mean ±S.D. 
1 2 3 4 5 6 
Day 7 134 148 159 126 114 149 138.33±16.71 
Day 14 122 `149 124 133 152 115 132.5±15.1 
 
Results were analysed using the following statistical test. 
IBM SPSS (statistical package for social sciences) software version 20 
was used for statistical analysis. 
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Statistical test used in this experiment 
One-way ANOVA (analysis of variance) 
In this study five independent groups were compared, so ANOVA was 
used for analysis which is an extension of student t test (which is for the 
comparison of two groups). One-way ANOVA was used because there is a 
independent variable and single dependent variable. It was used to identify 
statistical difference between the mean immobility periods of the five 
independent groups. There by it disproves “null hypothesis”. 
POST HOC TEST 
Bonferroni post hoc test: 
Once it was resolved that that there was difference exists between the 
means among the five groups, to determine where the difference exist Bonferroni 
post hoc test was applied. It is most commonly used where an array of paired 
comparison are made i.e. one group is compared with all the other groups. 
TABLE: 6 Mean ± SD immobility period in seconds on Day 7 and Day 14 in 
all groups 
DAY CONTROL STANDARD TEST I TEST II TEST III 
Day 7 198.8±14.9 120.1±19** 131.8±25.7** 141.5±15.6** 138.33±16.7** 
Day 14 194.3 ± 11.4 126.8 ±13.4** 128.8± 12.5** 145.5±11.11** 132.5±15.1** 
 
**: Highly significant < 0.01 
77 
 
Result of One Way ANOVA and Post Hoc Test 
When the day 7 and day 14 results were compared and analyzed by one 
way anova. There is a difference in the mean immobility time between groups. F 
value is significant (<0.05) for the degree of freedom. 
Post Hoc Test 
After anova identified a significant difference, in order to find where the 
difference exist Bonferroni post hoc test were used. 
It showed there is a significant difference in the immobility period of 
standard and all three test groups on day 7 when compared with control group. 
The mean immobility period on day 7 in all groups 
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Similar to day 7, day 14 results of post hoc test exhibited a significant 
difference between control and all the other groups. 
Figure: The mean immobility period on day 14 in all groups    
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Both on day 7 and day 14, there is a significant difference in the 
immobility period when we compare control with all the other groups. The 
difference is not significant when we compare the corresponding groups on day 7 
and 14. 
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DISCUSSION 
Depression is a highly prevalent psychiatric illness globally; based on the 
recent studies prevalence is expected to increase. It affects all age groups like 
teenagers, adults and old age of both sexes. The incidence is more among 
women. And it’s on the rise among teenagers. It’s the prime reason for DALY 
succeeding cardio vascular disease. 
In patients affected by depression it augments the underlying medical 
illness; chronic medical illness is also associated with depression. The incidence 
of suicidal attempt is around 50%; 15% of those cohort die due to suicide57. 
Thereby the disease has to be corrected effectively and promptly. 
With better understanding of the pathogenesis of depression, it is a 
treatable disease. There are certain pitfalls in the pharmacotherapy of depression 
like lack of efficacy, late onset of therapeutic effectiveness, adverse reaction, and 
non compliance. So the necessity for newer drugs or a newer target is the need of 
the hour 
SSRIs are the commonly prescribed antidepressant. Statin is a 
hypolipidemic agent which is widely used. There is ample number of examples in 
the drug history where the drug in its post marketing surveillance was found to 
have new usages. Statin is an enigmatic drug because of its pleiotropic effect 
which makes it, a suitable candidate for investigational studies. In this study 
Statin was evaluated   for its antidepressant effect in Swiss albino mice by tail 
suspension method. 
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Among the methods for evaluating antidepressants, tail suspension test is 
extensively used behaviour model. It has higher sensitivity and predictability. It 
is also a well established model for drugs acting through SERT. 
In this study antidepressant property of statin was evaluated using tail 
suspension test by observing the changes in the immobility period. The variation 
in the immobility period was compared between groups. On day 7, in the tail 
suspension test there was a significant decrease in the duration of immobility in 
the standard group when compared with the control group. P value was < 0.01 
level. The changes in the immobility period among the three test groups were 
also significant at 0.01 levels when compared with the control. There was no 
significant difference among the three test groups i.e. rosuvastatin, atrovastatin, 
simvastatin. There is also no statistical difference between the standard and the 
test groups. 
On the day 14 also there was a significant decrease in immobility period in 
the standard when compared with the control. P value was < 0.0l.  The mice were 
highly mobile in the test groups as well; here also the difference was statistically 
significant at 0.01 levels when compared with control. Similar to day 7 value 
there was no statistical significance when compared among the three test groups 
or the test group with standard. By taking into account the values of day 7 and 14, 
the study has established the antidepressant property of statin in animal model 
that was comparable with that of fluoxetine. 
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When we interpret the day7 and day 14 results there was no significant 
difference in the immobility period between the corresponding groups. 
In a study completed by Perry F. Renshaw et al58. which is the prototype 
study for antidepressant effect of statin in animal models, they found that 
Lovastatin potentiate the sub effective dose of fluoxetine. In Sprague Dawley rats 
they used 5mg/kg of fluoxetine and 2mg/kg/day of lovastatin. Forced swim test 
was performed. Lovasatin along with flluoxetine decreased the percentage of 
immobility period. Lovastatin alone had no antidepressant effect. In our test 
statin alone exhibited antidepressant property which was comparable with that of 
fluoxetine. The variation may be due to recommended dose of the statin used in 
the study when compared to the potentiating dose of lovastatin. In another study 
by Pao-Yen Lin et al59., it was found that simvastatin exhibit antidepressant 
property in rats which were exposed to chronic stress. Dose of 5 and 10 mg/ kg 
were used for 14 days. The antidepressant effect was comparable  to that of 
imipramine, but there was no difference in the response between  the two doses. 
In this study, in addition to simvastatin other statins like atrovastatin and 
rosuvastatin also showed antidepressant effect on par with fluoxetine. 
Although animal studies support a beneficial role of statins in attenuating 
depressive symptoms, the mechanism by which it exhibits the antidepressant 
effects is speculative. In a study done by Stefan John et al60. statins increased the 
level of nitric oxide when tried in patient with hypercholesterolemia. In this 
study, fluvastatin treated group exhibited a significant enhancement in the 
83 
 
acetylcholine-induced increase in blood flow in the forearm when compared with 
the baseline. After infusion of NG-monomethyl-L-arginine (L-NMMA) the NO 
synthase inhibitor, there was a graded decrease in blood flow with increasing 
doses. Thereby statin increases NO synthesis.   In a study by Aiwu Cheng et al61. 
it was demonstrated that BDNF increases nNOS production during differentiation 
of neural progenitor cells and nitric oxide mediates the BDNF activity. So nitric 
oxide is involved in a positive feedback chain with BDNF. In a study by 
Xiaoguang Han et al62., simvastatin treatment after trauma reduced the myelin 
loss, increased the expression of trophic factors like BDNF and GDNF, and 
fastens functional recovery. Thereby we can correlate that depression attenuating 
activity may be due to NO and BDNF cycle. In a study done by Mitani et al. 63 
increased levels of glutamate in blood were found in patients with depressive 
disorder; glutamate is a excitatory neurotransmitter and its considered to be the 
mediator of exitotoxicity in degenerative disorder. This activity of glutamate is 
mediated through NMDA receptor. In a study done by Jovita Ponce et al statins 
decrease the NMDA receptor mediated activity, then they  play a role in 
decreasing the excitotoxicity by glutamate64. 
So statins promote the neurotropic mediated activity and counter the  
glutamate mediated excitotoxicity. In addition to this, statins also exhibit anti 
inflammatory, immunomodulatory and anti oxidant property.  It decreases the 
transcription of various inflammatory mediators and modulates the adhesion 
process at various points by targeting both leukocytes and endothelium. They 
inhibit cell chemokine expression, integrin expression, integrin activation in 
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leukocytes, stimulated endothelial cells, and monocytes65. The pro-inflammatory 
mediators IFN-α, IL-1β, NF-κB, IL-6  decreases the  nerve growth factor; 
similarly a decrease in anti-inflammatory mediators like IL-10 also associated 
with decrease in nerve growth factor. Thereby inflammation as a causative factor 
in depression provides newer targets against the disease. Anti –Inflammatory  and 
immunomodulatory property of statin  go hand in hand. Depressive disorder is 
associated with immunological abnormalities like lymphocyte mediated increase 
of CRF, Cytokines and Interleukins66. The oxidative stress play an important role 
in depression .In a study by Kyoko meji et al67. they ensures  Pitavastatin 
enhances  the Cu/Zn Super Oxide Dismutase (SOD) and PPAR-gamma 
expression, they also inhibit NAD(P)H oxidase activity .This explains  
antioxidant property of statin. There is a paradigm shift in the pathogenesis of 
depression from monoamine hypothesis to neurotropic hypothesis. Statin seems 
to counter the various pathological factors of depression through  it’s pleiotropic 
effect. 
Finally the vascular depression which happens in old age; it is 
characterised by hyper intense lesion on MRI (magnetic resonance imaging) and 
high degree of resistance to antidepressants. The pathophysiological basis is 
inflammation and hemodynamic changes. It results in altered function due to 
hypoperfusion which will end up in depression68. Statin due to its pleiotropic 
effect may reduce the variation in microvascular resistance. In addition to this, 
inhibition of Rac1 phrenylation in endothelial cells induces the expression of a 
wide range of genes implicated in neurovascular protection69. 
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Overall, the precise mechanism by which statin exhibit antidepressant 
property is not clear. Various neurotropic activity and anti-inflammatory, 
immunomodulatory, antioxidant property acts in a cumulative manner to improve 
functional outcome and may contribute to the overall antidepressant activity of 
statins. 
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CONCLUSION 
Major depressive illness is a heterogeneous disorder with high morbidity 
and mortality. The heterogeneity is because of its integrated etiological model. 
The disease is often misdiagnosed and undertreated. With the availability of 
newer antidepressants the disease is very much treatable. There are certain snags 
in the pharmacotherapy of depression like therapeutic lag, decreased compliance, 
adverse reaction and also 30% of patients remain non responders to the available 
antidepressants. 
In this study statin was evaluated for its antidepressant property by tail 
suspension method. It exhibited antidepressant effect which was statistically 
significant and was comparable with that of fluoxetine. Thereby the study 
objective was completed. 
Depression is frequently associated with medical conditions like 
cardiovascular illness arthritis, stroke. On the other side depression is also an 
individual risk factor for cardio and cerebrovascular diseases, the use of statin 
can be more justified in these conditions.  Statins has the potential to be used as 
an adjuvant in the treatment of depression, particularly in the treatment of 
resistant depression and vascular depression. 
Further animal studies involving large number of animals, other 
models of depression are needed. It can also help us to know the target through 
which statins act and based on targets new lead molecules can be generated. 
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MASTER CHART 
MASTER CHART 
 
Day 7 immobility time in seconds 
 
S.NO Control standard Test I Test II Test III 
Mouse-1 205 109 142 144 134 
Mouse-2 192 121 115 118 148 
Mouse-3 175 110 96 162 159 
Mouse-4 220 105 155 132 126 
Mouse-5 203 157 120 154 114 
Mouse-6 198 119 163 139 149 
 
  
Day 14 immobility time in seconds 
S.NO Control standard Test I Test II Test III 
Mouse-1 181 144 133 136 122 
Mouse-2 211 115 108 142 149 
Mouse-3 187 117 126 155 124 
Mouse-4 202 134 130 147 133 
Mouse-5 199 138 147 161 152 
Mouse-6 186 113 129 132 115 
ABBREVIATION 
 WHO   World Health Organisation  
CBT    Cognitive Behaviour Therapy  
TCA   Tricyclic Antidepressants  
MAOIs  Monoamine Oxidase Inhibitors 
SSRIs   Selective Serotonin Reuptake Inhibitors  
SNRIs   Serotonin nor adrenaline Reuptake Inhibitors  
MMD   Major Mood Disorder  
DALY  Disability adjusted life year  
PPD   Post Partum Depression  
5-HT    5-Hydroxy Tryptamine  
NA   Nor adrenaline 
CSF   Cerebro Spinal Fluid 
CRH   Corticotrophin-releasing hormone  
TRH   TSH releasing hormone 
ACTH   Adrenocorticotrophic hormone  
BDNF   Brain-Derived Neurotrophic Factor   
AIDS   Acquired Immuno Deficiency Syndrome 
DSM-V   Diagnostic and Statistical Manual of Mental Disorders-V  
PMDD   Premenstrual Dysphoric Disorder   
ECT   Electro Convulsive Therapy  
RIMA             Reversible MAO-A-selective inhibitors  
IPT   Inter Personal Therapy 
FDA  Federal Drug Agency  
TMS  Transcranial Magnetic Stimulation  
SERT  Serotonin reuptake transporter  
CYP   Cytochrome p 450 
OCD   Obsessive Compulsive Disorder. 
CTZ  Chemoreceptor Trigger Zone. 
NET   Nor epinephrine transporter   
NMDA  N-Methyl-D-aspartate 
AMPA             α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
MIF-1         Melanocyte inhibiting factor- 1  
LDL Low density lipoprotein 
HMG CO-A           3-Hydroxy- 3 Methyl Glutaryl Coenzyme A.  
 NO  Nitric oxide 
EPC  Endothelial Progenitor Cell 
eNOS  Endothelial nitric oxide synthase 
NFkB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
INF  INTERFERON 
MCH II Major Histocompatibility Complex II 
MMP  Matrix metalloproteinase 
NADPH  Nicotinamide adenine dinucleotide phosphate  
BMP  Bone morphogenic protein 
CPK            Creatine phosphokinase 
CVD   Cardio Vascular Diseases  
MI  Myocardial Infarction 
CPCSEA  Committee for the Purpose of Controlled Supervision of      
Experimentation on Animals  
ANOVA  Analysis of Variance 
L-NMMA              NG-monomethyl-L-arginine  
GDNF Glial Derived NeurotropicFactor. 
IL     Interleukin 
SOD  Super Oxide Dismutase  
PPAR Peroxisome Proliferator-Activated Receptor. 
MRI  Magnetic Resonance Imaging. 
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